Key facts
- Notable investors include Criabiz Ventures, Rock9 Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for FABP Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for FABP Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FABP Biotech
Manufacturer of animal vaccines designed for the prevention of parasitic infections. The company develops and commercializes vaccines based on the Sm14 protein, including a vaccine for fasciolosis in livestock and another for heartworm and other parasitic worms in pets, enabling animal owners and veterinarians to protect animals from these common and potentially harmful infections.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Rio de Janeiro, Brazil
- Founded
- 2020
- Employees
- 10
- Website
- fabpbiotech.com.br/
- Ownership
- Privately Held (backing)
FABP Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FABP Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FABP Biotech in its N-PORT filings yet. We sweep new filings monthly.